APLIF - Appili provides recruitment update on late-stage COVID-19 PRESECO trial

Appili Therapeutics ([[APLIF]] -2.8%)  announced that its Phase 3 PRESECO (PREventing SEvere COvid-19) clinical trial is actively recruiting participants in 12 out of 20 planned sites in the United States.Appili said it will prioritize resources to accelerate recruitment and data analysis for the PRESECO study, and expects to reach the enrollment threshold required to provide an interim data readout by late March 2021.The company plans to recruit about  826 eligible participants, who are recently diagnosed as COVID-19 positive with mild to moderate symptoms, for the study evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.The Phase 3 PRESECO study is a double blinded, placebo-controlled multi-center trial investigating the safety and efficacy of favipiravir in the early treatment outpatient setting for adults infected with COVID-19 and showing mild to moderate symptoms.

For further details see:

Appili provides recruitment update on late-stage COVID-19 PRESECO trial